Physician profile
Julia Wortham
NPI 1205440278
$8,542.07
in general payments reported to CMS, 2019-2025
32 companies · $5,997 in 2025
The $5,997 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $319 · 2022: $967 · 2023: $824 · 2024: $435 · 2025: $5,997.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,260 · Consulting Fee: $1,627 · Education: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,259.52 |
| Consulting Fee | $1,626.50 |
| Education | $369.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,004.69 | 2025 | Cabtreo, Jublia, Siliq |
| E.R. Squibb & Sons, L.L.C. | $940.34 | 2023-2025 | Sotyktu |
| Genzyme Corporation | $606.33 | 2025 | |
| Amgen INC. | $468.79 | 2021-2025 | Otezla |
| Arcutis Biotherapeutics, INC. | $446.33 | 2023-2025 | Zoryve |
| Ucb, INC. | $430.78 | 2024-2025 | Bimzelx |
| Abbvie INC. | $408.32 | 2021-2025 | |
| Axonics, INC. | $391.86 | 2022 | |
| Janssen Biotech, INC. | $388.82 | 2024-2025 | Tremfya |
| Galderma Laboratories, L.P. | $345.44 | 2025 | Nemluvio |
| Novartis Pharmaceuticals Corporation | $332.05 | 2025 | |
| Leo Pharma INC. | $310.59 | 2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $282.87 | 2024-2025 | Ebglyss, Taltz |
| Abbott Laboratories | $232.73 | 2022-2023 | Proclaim |
| Astrazeneca Pharmaceuticals LP | $228.20 | 2022-2023 | Fasenra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $209.73 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $207.61 | 2023 | |
| Pfizer INC. | $180.32 | 2025 | |
| Sanofi-Aventis U.S. LLC | $169.98 | 2025 | |
| Organon LLC | $156.56 | 2025 | Hadlima |
| Regeneron Healthcare Solutions, INC. | $123.93 | 2024-2025 | Dupixent |
| Biohaven Pharmaceutical Holding Company LTD. | $123.59 | 2022 | |
| Novo Nordisk INC | $120.00 | 2023 | Ozempic |
| Antares Pharma, INC. | $105.09 | 2023 | Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $102.07 | 2022 | |
| Smith+Nephew, INC. | $69.62 | 2021 | |
| Convatec INC. | $43.87 | 2025 | |
| Almirall LLC | $33.66 | 2025 | Klisyri |
| Bioventus LLC | $27.90 | 2021 | |
| Biofrontera INC. | $21.17 | 2025 | |
| Janssen Scientific Affairs, LLC | $16.02 | 2025 | Tremfya |
| Stryker Corporation | $12.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Wortham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.